Clinical practice experience with nirmatrelvir/ritonavir as treatment for COVID-19 in patients with multiple sclerosis on immunosuppressive therapy

Authors
Category Primary study
ConferenceMSmilan2023
Year 2023
This article has no abstract
Epistemonikos ID: cad635b3876ede8e2619f71ced122aba33563b14
First added on: Jan 07, 2026